Company Overview and News
2018-08-13 seekingalpha - 5
Ultra Petroleum Corp (UPL) is in trouble. After exiting Ch.11 in April 2017, they still have way too much debt. Recently management announced problems with their expensive horizontal drilling and that they are selling their Utah oil assets for only $75 million, which they paid $650 million. The stock price has plunged from the Ch.11 estimated equity plan value for new UPL shares of $17.30 to only $1.
UPL REXX BBPPQ RXNRP REXXQ BBEP UPLMQ BBEPQ BBEPP
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE
2018-04-16 seekingalpha - 3
After a 20% run-up in Club stocks in January, prices declined the rest of the quarter by -25%, with the Club finishing with an average return of -9%.
ECR CRC LGCYP LGCYO CRK REN EPE SCAZP BBEP MCEP MCF AREX RXNRP JNEEP XCOO SNZYP BBEPP SN BBPPQ EVEP JONE XCO REXX DNR LGCY WTI BBEPQ PQ
LOS ANGELES--(BUSINESS WIRE)--Maverick Natural Resources, LLC (“Maverick”), announced today that it began operating on April 6, 2018, after it emerged from Chapter 11 as the successor to Breitburn Energy Partners LP (“Breitburn”). Maverick is majority-owned and controlled by funds and accounts managed by EIG Global Energy Partners (“EIG”).
BBPPQ BBEP BBEPQ BBEPP
2018-03-12 rigzone - 1
March 12 (Reuters) - Breitburn Energy Partners LP has reached an agreement with holdout creditors over its $3 billion bankruptcy exit plan and hopes to win court confirmation as soon as this month for a reorganization under new ownership, a lawyer said on Monday.
BBPPQ BBEP BBEPQ BBEPP
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET